【浙商医药|孙建】科济药业24年:CT041即将NDA,通用型多线推进

杏林建研
31 Mar

分析师:孙 建(S1230520080006)郭双喜(S1230521110002)来源:浙商证券医药研究团队具体参见2025年3月26日报告《CT041即将NDA,通用型多线推进——科济药业2024年报业绩点评》,如需报告全文或数据底稿,请联系团队成员或对口销售。投资要点CT053已经开始贡献业绩,CT041即将NDA,通用型CAR-T多管线推进,我们看好公司在实体瘤CAR-T和通用型...

Source Link

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

  1. 1
     
     
     
     
  2. 2
     
     
     
     
  3. 3
     
     
     
     
  4. 4
     
     
     
     
  5. 5
     
     
     
     
  6. 6
     
     
     
     
  7. 7
     
     
     
     
  8. 8
     
     
     
     
  9. 9
     
     
     
     
  10. 10